Drugs News and Research

RSS

Roundup: Legislatures pressured on health cuts, malpractice laws; Mass. Blue Cross board salaries; pension costs

This week, the Assembly and Senate will debate the final package of budget reductions. Among the $6 billion in health-related cuts is the elimination of the Maddy Fund, a $55 million attempt to reimburse emergency departments for indigent care.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

The American Journal of Medicine focuses on the continuing healthcare reform debate

As the debate about healthcare in the United States rages, four insightful articles in the March 2011 issue of The American Journal of Medicine strive to add reasoned arguments and empirical research findings to the dialog.

9 Mar 2011

Variation in exposure to sunlight may affect sensitivity of individuals to drugs

A study from the Swedish medical university Karolinska Institutet has shown that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons.

9 Mar 2011

Prolonged exposure to antidepressants can induce tardive dysphoria

In the current issue of Psychotherapy and Psychosomatics a new important side effect of antidepressant drugs is described: tardive dysphoria.

9 Mar 2011

Overall survival rate for ovarian cancer have increased over last 30 years

Survival from ovarian cancer has almost doubled over the last 30 years according to new figures from Cancer Research UK released today.

9 Mar 2011

NCCN, SNM enter cancer imaging research collaboration

The National Comprehensive Cancer Network- (NCCN-), and the Society of Nuclear Medicine (SNM) are pleased to announce a collaboration to advance research for cancer imaging and therapies. Specifically, NCCN will work with SNM to qualify imaging sites for upcoming research projects utilizing molecular imaging in clinical trials.

9 Mar 2011

Apotex passes Bill C-393 to fix Canada's Access to Medicines Regime

Apotex Inc, Canada's largest pharmaceutical company, today underscored the need for Members of Parliament to fix Canada's Access to Medicines Regime by passing Bill C-393 when it comes up for final vote tomorrow, March 9, 2011.

9 Mar 2011

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

Researchers at the University of California, Davis have discovered a "cross-talk" between two major biological pathways that involve pain-research that may pave the way to new approaches to understanding and controlling chronic pain.

9 Mar 2011

Multiple target therapy may treat HER2-positive breast cancers

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center investigators.

9 Mar 2011

Parkinson's disease medication turns on critical gene, protects brain cells

In a major breakthrough in the battle against Parkinson's disease, researchers at the University of Colorado School of Medicine have discovered a drug that stops the progression of the degenerative illness in mice and is now being tested in humans.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

NHMRC awards $38.4M for cancer and blood cell research

Institute research into how cancer develops and blood cell production and function will today be awarded $38.4 million under the National Health and Medical Research Council's (NHMRC) program grants scheme.

9 Mar 2011

Patients with epilepsy-linked memory loss worry more than their physicians

Patients with epilepsy worry more than their physicians do about the patients' potential memory loss accompanying their seizure disorder, according to a recent study.

9 Mar 2011

Chemist discover new strategy to process certain drugs

A prolific University of Missouri chemist has discovered a quicker and easier method for pharmaceutical companies to make certain drugs.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

Smart technology for healthy longevity

A national policy is required for the research, demonstration, commercialisation and wide-scale deployment of smart technology for ageing-in-place to ensure: a healthy, safe, secure and fulfilling future for the increasing aged population in Australia by enabling them to remain at home longer, by easing the strain on the national healthcare system and providing cost effective solutions to meet the needs of the growing number of elderly Australians.

9 Mar 2011

Conflicts of interest overlooked in drug trial reviews: Study

A new study shows that researchers who review large sets of drug trials for medical journals – also known as meta analysis - often ignore financial conflicts that might affect the evidence and thereby conclusions.

8 Mar 2011

Single-wall carbon nanotubes targeted and killed cancer cells without harming the healthy cells

SouthWest NanoTechnologies’ (SWeNT) Single-Wall Carbon Nanotubes (SWCNT) exhibit promising potential for use in biomedical treatments such as cancer photo thermal therapies, new research reveals.

8 Mar 2011